AC
NMRA icon

AlphaCore Capital’s Neumora Therapeutics NMRA Stock Holding History

AlphaCore Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Hold
638,784
– – 0.03% 332
2025
Q4 		$1.14M Hold
638,784
– – 0.03% 386
2025
Q3 		$1.16M Buy
638,784
+301,017
+89% +$487K 0.04% 274
2025
Q2 		$248K Buy
+337,767
New +$256K 0.01% 531

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

AlphaCore Capital's NMRA Position: Q1 2026 in Review

AlphaCore Capital held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 638,784 shares worth $1.25M. The position accounts for 0.03% of the portfolio, ranked #332.

AlphaCore Capital first reported a position in NMRA in Q2 2025 and has held it in 4 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • AlphaCore Capital held 638,784 shares of Neumora Therapeutics worth $1.25M as of Q1 2026.
  • AlphaCore Capital left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up 0.03% of AlphaCore Capital's portfolio in Q1 2026, its #332 holding.
  • AlphaCore Capital first reported a position in Neumora Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.